Author

J. Roma

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

S. Gallego· 4 shared J. Sanchez de Toledo· 3 shared L. Moreno· 3 shared M. F. Segura· 3 shared N. Navarro· 3 shared A. Soriano· 2 shared G. Pons· 2 shared J. Sansa-Girona· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

S. Gallego

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma

G. O. Gallo-Oller, G. Pons, J. Sansa-Girona, N. Navarro, P. Zarzosa, L. Garcia-Gilabert, P. Cabre Fernandez, G. Guillen Barrieza, L. Valero-Arrese, M. F. Segura, J. M. Lizcano, J. Sanchez de Toledo, L. Moreno, S. Gallego, J. Roma

This study shows TRIB3 silencing reduces Akt pathway activity and PAX3-FOXO1 levels in high-risk rhabdomyosarcoma, leading to decreased tumor growth and improved survival.

bioRxiv · Dec 1, 2023Cancer Biology

Analysis of cancer genomic amplifications identifies druggable collateral dependencies within the amplicon

G. Pons, G. Gallo-Oller, N. Navarro, P. Zarzosa, J. Sansa-Girona, L. Garcia-Gilabert, A. Magdaleno, M. F. Segura, J. Sanchez de Toledo, S. Gallego, L. Moreno, J. Roma

The paper identifies druggable collateral dependencies in cancer genomic amplifications using CRISPR/Cas9 screens and integrates gene dependency with druggability and subcellular location data.

bioRxiv · Nov 16, 2022Cancer Biology

Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program

C. Jimenez, R. Antonelli, M. Nadal-Ribelles, L. Devis-Jauregui, P. Latorre, C. Sole, M. Masanas, A. Molero-Valenzuela, A. Soriano, J. Sanchez de Toledo, D. Llobet-Navas, J. Roma, F. Posas, E. de Nadal, S. Gallego, , M. F. Segura

This study shows that disrupting the BAF chromatin remodeller in neuroblastoma cells reduces metastasis by repressing an invasiveness-related epigenomic program.

bioRxiv · May 17, 2022Cancer Biology

Single-cell mapping of tumor heterogeneity in pediatric rhabdomyosarcoma reveals developmental signatures with therapeutic relevance

S. G. Danielli, E. Porpiglia, A. J. De Micheli, N. Navarro, M. J. Zellinger, I. Bechtold, S. Kisele, L. Volken, J. G. Marques, S. Kasper, P. K. Bode, A. G. Henssen, D. Gürgen, J. Roma, P. Bühlmann, , B. W. Schäfer

This study maps tumor heterogeneity in pediatric rhabdomyosarcoma using single-cell data, revealing developmental signatures and identifying the RAS pathway as a therapeutic target.

bioRxiv · Apr 20, 2022 · PreprintCancer Biology

Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance.

C. Alcon, A. Manzano-Munoz, E. Prada, J. Mora, A. Soriano, G. Guillen, S. Gallego, J. Roma, J. Samitier, A. Villanueva, J. Montero

This study uses dynamic BH3 Profiling to identify BH3 mimetic combinations that enhance chemotherapy efficacy and prevent resistance in rhabdomyosarcoma.

bioRxiv · Jan 24, 2020Cancer Biology